Inventor · disambiguated record
Sherri Van Everen
Also filed as: VAN EVEREN SHERRI
0 granted patents·14 pending applications·0 citations·filing 2018–2025
Files withREGENXBIO INC14
Top patents by PatentIndex Score
14 records- 0172US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0264US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0357US2025276097A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0455US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 0552US2025339555A1Formulations for suprachoroidal administration such as formulations with aggregate formationREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0646US2020093939A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2019·Application pending·0 cites
- 0745US2024024508A1Formulations for suprachoroidal administration such as high viscosity formulationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 0845US2023414788A1Formulations for suprachoroidal administration such as gel formulationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 0943US2022143221A1Gene Therapy For Eye PathologiesREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1043US2022195462A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1142US2023372538A1Formulations for suprachoroidal administration such as formulations with aggregate formationREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1241US2023364206A1Gene therapy for ocular manifestations of cln2 diseaseREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1339US2022280608A1Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fabREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1437US2021010025A1Treatment of ocular diseases with human post-translationally modified vegf-trapREGENXBIO INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sherri Van Everen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →